Eagle Rock Investment Company LLC Boosts Position in Cencora, Inc. (NYSE:COR)

Eagle Rock Investment Company LLC boosted its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 2.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 39,040 shares of the company's stock after acquiring an additional 1,048 shares during the quarter. Cencora accounts for 1.5% of Eagle Rock Investment Company LLC's portfolio, making the stock its 17th biggest holding. Eagle Rock Investment Company LLC's holdings in Cencora were worth $8,772,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. Concord Wealth Partners purchased a new position in shares of Cencora during the 3rd quarter worth $30,000. SYSTM Wealth Solutions LLC purchased a new position in Cencora during the second quarter valued at $36,000. Ashton Thomas Securities LLC purchased a new position in Cencora during the third quarter valued at $41,000. Fairscale Capital LLC bought a new stake in Cencora during the second quarter valued at about $54,000. Finally, Modus Advisors LLC purchased a new stake in Cencora in the fourth quarter worth about $54,000. Institutional investors own 97.52% of the company's stock.

Insider Activity at Cencora

In related news, EVP Silvana Battaglia sold 1,678 shares of the firm's stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the sale, the executive vice president now directly owns 20,329 shares in the company, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Steven H. Collis sold 21,509 shares of the business's stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the transaction, the chairman now owns 285,088 shares in the company, valued at $67,223,750.40. This trade represents a 7.02 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 94,696 shares of company stock valued at $22,862,734. Insiders own 15.80% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on COR shares. StockNews.com downgraded Cencora from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 20th. Evercore ISI raised their price objective on shares of Cencora from $250.00 to $285.00 and gave the company an "outperform" rating in a research report on Thursday, November 7th. Robert W. Baird upped their target price on shares of Cencora from $287.00 to $292.00 and gave the stock an "outperform" rating in a report on Thursday, November 7th. Leerink Partners cut their price target on Cencora from $277.00 to $275.00 and set an "outperform" rating for the company in a research note on Monday, October 7th. Finally, Wells Fargo & Company lowered their price objective on Cencora from $249.00 to $237.00 and set an "equal weight" rating on the stock in a research report on Friday, December 13th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, Cencora presently has a consensus rating of "Moderate Buy" and an average target price of $275.60.

Cencora Price Performance

Shares of NYSE:COR traded up $1.22 during mid-day trading on Friday, reaching $242.11. The stock had a trading volume of 1,492,998 shares, compared to its average volume of 1,280,327. The business's 50 day moving average price is $237.52 and its 200 day moving average price is $233.85. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $253.27. The company has a market cap of $46.80 billion, a P/E ratio of 32.24, a price-to-earnings-growth ratio of 1.48 and a beta of 0.49. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.91%. This is a boost from Cencora's previous quarterly dividend of $0.51. The ex-dividend date of this dividend was Friday, November 15th. Cencora's dividend payout ratio is currently 29.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.